Redmile Group LLC Has $48.24 Million Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Redmile Group LLC increased its holdings in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 18.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,326,509 shares of the company’s stock after buying an additional 667,245 shares during the period. ALX Oncology comprises approximately 1.8% of Redmile Group LLC’s portfolio, making the stock its 18th largest position. Redmile Group LLC owned 8.30% of ALX Oncology worth $48,241,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. EntryPoint Capital LLC bought a new stake in shares of ALX Oncology in the first quarter worth $32,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of ALX Oncology in the 1st quarter valued at about $27,000. Vanguard Group Inc. increased its stake in shares of ALX Oncology by 4.3% in the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after buying an additional 64,055 shares during the period. Inspire Investing LLC bought a new position in shares of ALX Oncology during the first quarter worth about $370,000. Finally, Swiss National Bank acquired a new position in shares of ALX Oncology in the first quarter worth approximately $493,000. 97.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, May 29th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research report on Monday, June 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, ALX Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

ALX Oncology Stock Down 3.3 %

NASDAQ ALXO traded down $0.20 on Monday, hitting $5.85. 977,555 shares of the company were exchanged, compared to its average volume of 632,018. The company has a market cap of $304.79 million, a PE ratio of -1.57 and a beta of 1.06. ALX Oncology Holdings Inc. has a 12 month low of $3.94 and a 12 month high of $17.83. The stock has a fifty day moving average of $8.06 and a 200-day moving average of $12.09. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. As a group, analysts forecast that ALX Oncology Holdings Inc. will post -2.89 earnings per share for the current year.

Insider Buying and Selling at ALX Oncology

In related news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the transaction, the insider now owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Sophia Randolph sold 12,000 shares of ALX Oncology stock in a transaction on Monday, May 13th. The stock was sold at an average price of $15.94, for a total transaction of $191,280.00. Following the sale, the insider now directly owns 330,349 shares in the company, valued at $5,265,763.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the transaction, the insider now directly owns 604,205 shares in the company, valued at approximately $5,093,448.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,469 shares of company stock valued at $873,346. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.